The Benefit of Maintaining the Expression of the Anti-sickling Damma Ortholog in Patients With Sickle Cell Disease and Beta-thalassemias
Pharmacy Times® interviewed Christopher Moxham of Fulcrum Therapeutics, on how maintaining expression of the anti-sickling gamma ortholog could be beneficial for children and adults with sickle cell disease, and why this is important to investigate.
Pharmacy Times® interviewed Christopher Moxham, the senior vice president of discovery research at Fulcrum Therapeutics, on his presentation at the 62nd ASH Annual Meeting and Exposition. The presentation discusses research into the induction of fetal hemoglobin by FTX6058, a novel small molecule development candidate.
In this video, Moxham explains how maintaining expression of the anti-sickling gamma ortholog could be beneficial for children and adults with sickle cell disease, and why this is important to investigate.
